PRMT5 and laryngeal carcinoma: Next, we used the Wnt/β-catenin pathway-specific inhibitor XAV939 or activator LiCl to treat laryngeal carcinoma cells for 96 h; the PRMT5-mediated proliferation in Tu212 and Tu686 cells was dramatically suppressed or restarted, respectively (Fig. 4h, i).